BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 29523675)

  • 1. Chimeric Antigen Receptor T Cell Therapy and the Kidney: What the Nephrologist Needs to Know.
    Jhaveri KD; Rosner MH
    Clin J Am Soc Nephrol; 2018 May; 13(5):796-798. PubMed ID: 29523675
    [No Abstract]   [Full Text] [Related]  

  • 2. Chimeric antigen receptor T cell therapy and nephrotoxicity: From diagnosis to treatment strategies.
    Zhou H; Yang M; Cui L; Jiang J
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107072. PubMed ID: 33059198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor (CAR) T-Cell Therapy.
    Pagel JM; West HJ
    JAMA Oncol; 2017 Nov; 3(11):1595. PubMed ID: 28880983
    [No Abstract]   [Full Text] [Related]  

  • 4. CAR T-cells for relapsed B-cell ALL in adults.
    Gilbert JA
    Lancet Oncol; 2018 Mar; 19(3):e143. PubMed ID: 29429915
    [No Abstract]   [Full Text] [Related]  

  • 5. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
    Ma T; Shi J; Liu H
    Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
    Strati P; Neelapu SS
    Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
    Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
    Front Immunol; 2018; 9():239. PubMed ID: 29515572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Le Bourgeois A
    Bull Cancer; 2018 Dec; 105 Suppl 2():S188-S197. PubMed ID: 30686357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
    Hunter BD; Rogalski M; Jacobson CA
    Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
    [No Abstract]   [Full Text] [Related]  

  • 10. Chimeric Antigen Receptor T-Cell Therapy: What the Neuroradiologist Needs to Know.
    Valand HA; Huda F; Tu RK
    AJNR Am J Neuroradiol; 2019 May; 40(5):766-768. PubMed ID: 31048298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beginning the CAR T cell therapy revolution in the US and EU.
    Grupp S
    Curr Res Transl Med; 2018 May; 66(2):62-64. PubMed ID: 29656949
    [No Abstract]   [Full Text] [Related]  

  • 12. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR T-cells for relapsed B-cell ALL in children and young adults.
    Stirrups R
    Lancet Oncol; 2018 Mar; 19(3):e144. PubMed ID: 29429913
    [No Abstract]   [Full Text] [Related]  

  • 14. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy.
    Han X; Wang Y; Wei J; Han W
    J Hematol Oncol; 2019 Nov; 12(1):128. PubMed ID: 31783889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor T cell therapies for multiple myeloma.
    Wu C; Zhang L; Brockman QR; Zhan F; Chen L
    J Hematol Oncol; 2019 Nov; 12(1):120. PubMed ID: 31752943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead.
    Zhang Q; Ping J; Huang Z; Zhang X; Zhou J; Wang G; Liu S; Ma J
    J Immunol Res; 2020; 2020():1924379. PubMed ID: 32411789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
    Ghassemi S; Milone MC
    J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.